HomeCompareKBBTF vs NNN

KBBTF vs NNN: Dividend Comparison 2026

KBBTF yields 208.33% · NNN yields 5.66%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 KBBTF wins by $151.46M in total portfolio value
10 years
KBBTF
KBBTF
● Live price
208.33%
Share price
$0.96
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$151.48M
Annual income
$77,914,744.95
Full KBBTF calculator →
NNN
NNN REIT Inc.
● Live price
5.66%
Share price
$42.03
Annual div
$2.38
5Y div CAGR
8.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$25.5K
Annual income
$2,622.67
Full NNN calculator →

Portfolio growth — KBBTF vs NNN

📍 KBBTF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodKBBTFNNN
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, KBBTF + NNN cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
KBBTF pays
NNN pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

KBBTF
Annual income on $10K today (after 15% tax)
$17,708.33/yr
After 10yr DRIP, annual income (after tax)
$66,227,533.21/yr
NNN
Annual income on $10K today (after 15% tax)
$481.32/yr
After 10yr DRIP, annual income (after tax)
$2,229.27/yr
At 15% tax rate, KBBTF beats the other by $66,225,303.94/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of KBBTF + NNN for your $10,000?

KBBTF: 50%NNN: 50%
100% NNN50/50100% KBBTF
Portfolio after 10yr
$75.75M
Annual income
$38,958,683.81/yr
Blended yield
51.43%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on NNN right now

KBBTF
No analyst data
NNN
Analyst Ratings
10
Buy
15
Hold
4
Sell
Consensus: Hold
Price Target
$44.93
+6.9% upside vs current
Range: $43.00 — $48.50
Altman Z
1.1
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

KBBTF buys
0
NNN buys
2
PoliticianChamberTickerTypeAmountDate
Lisa McClain🏢 House$NNN▼ Sell$1,001 - $15,0002025-08-13
Lisa McClain🏢 House$NNN▲ Buy$1,001 - $15,0002025-06-17
Zoe Lofgren🏢 House$NNN▼ Sell$1,001 - $15,0002023-05-25
Ro Khanna🏢 House$NNN▼ Sell$1,001 - $15,0002022-01-20
Zoe Lofgren🏢 House$NNN▲ Buy$1,001 - $15,0002021-09-30
Zoe Lofgren🏢 House$NNN▼ Sell$1,001 - $15,0002020-03-23
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricKBBTFNNN
Forward yield208.33%5.66%
Annual dividend / share$2.00$2.38
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%8.6%
Portfolio after 10y$151.48M$25.5K
Annual income after 10y$77,914,744.95$2,622.67
Total dividends collected$143.08M$13.7K
Payment frequencyquarterlyquarterly
SectorStockREIT

Year-by-year: KBBTF vs NNN ($10,000, DRIP)

YearKBBTF PortfolioKBBTF Income/yrNNN PortfolioNNN Income/yrGap
1← crossover$31,533$20,833.33$10,735$614.96+$20.8KKBBTF
2$95,137$61,396.68$11,572$708.43+$83.6KKBBTF
3$274,915$173,118.00$12,531$819.53+$262.4KKBBTF
4$761,685$467,526.04$13,633$952.29+$748.1KKBBTF
5$2,025,599$1,210,595.57$14,909$1,111.84+$2.01MKBBTF
6$5,176,190$3,008,799.54$16,392$1,304.77+$5.16MKBBTF
7$12,724,177$7,185,654.07$18,129$1,539.52+$12.71MKBBTF
8$30,123,158$16,508,287.86$20,173$1,827.08+$30.10MKBBTF
9$68,756,679$36,524,900.02$22,597$2,181.81+$68.73MKBBTF
10$151,484,391$77,914,744.95$25,491$2,622.67+$151.46MKBBTF

KBBTF vs NNN: Complete Analysis 2026

KBBTFStock

Kubota Pharmaceutical Holdings Co., Ltd. develops portfolio of drugs and devices in the ophthalmic field worldwide. Its product pipeline comprises emixustat hydrochloride, which is in Phase III clinical stage used for the treatment of stargardt disease, and Phase II clinical stage used for the treatment of proliferative diabetic retinopathy. The company is also developing remote retinal monitoring device, a home-based and patient self-monitoring optical coherence tomography devices to treat wet age-related macular degeneration and diabetic macular edema, which brings retinal edema and reduction in visual acuity; and wearable device for myopia control. The company was founded in 2002 and is based in Tokyo, Japan.

Full KBBTF Calculator →

NNNREIT

National Retail Properties invests primarily in high-quality retail properties subject generally to long-term, net leases. As of September 30, 2020, the company owned 3,114 properties in 48 states with a gross leasable area of approximately 32.4 million square feet and with a weighted average remaining lease term of 10.7 years.

Full NNN Calculator →
📬

Get this KBBTF vs NNN comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

KBBTF vs SCHDKBBTF vs JEPIKBBTF vs OKBBTF vs KOKBBTF vs MAINKBBTF vs ADCKBBTF vs EPRTKBBTF vs FCPT

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.